The primary objective was to compare CD8+ TIL at the time of surgery in the two arms with the hypothesis being that there would be an increased proportion of CD8+ TIL in the combined durvalumab plus tremelimumab group resulting in an amplified anti-tumor response. The gene discussed is CD8A; the disease is neoplasm.